| Filed On | Filing |
|---|---|
| 09 Nov 2026 | 10-Q |
| 09 Nov 2026 |
8-K: Results of Operations and Financial Condition
ImmunityBio Reports Label Expansion and Additional Global Approval with Q3 2026 Net Product Revenue of $48.7 Million, Up 53% Year-Over-Year and First Nine Months U.S. Revenue Up 92% to $143.6 Million |
| 09 Nov 2026 |
8-K: Regulation FD Disclosure
CULVER CITY, Calif., November 9, 2026—ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced positive results from the final analysis of the primary endpoint in Cohort A of QUILT-2.005, a randomized, ... |
| 14 Oct 2026 |
8-K: Regulation FD Disclosure
FDA Expands ANKTIVA® Approval for BCG-Unresponsive Non-Muscle- Invasive Bladder Cancer to Cover Both Papillary and CIS Disease |
| 06 Oct 2026 |
Form 4: Simon Barry J., Director
Sold 25,000 shares ($269K) |
| 06 Oct 2026 |
Form 4: Cohen Cheryl, Director
Received 55,979 shares by exercise or conversion ($167K) · Sold 81,056 shares ($851K) |
| 05 Oct 2026 | 144 |
| 02 Oct 2026 | 144 |
| 06 Aug 2026 | SCHEDULE 13D/A |
| 04 Aug 2026 | 10-Q |
| 04 Aug 2026 |
8-K: Results of Operations and Financial Condition
CULVER CITY, Calif. August 4, 2026 — ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage biotechnology company, today announced financial and operational results for the second quarter ended June 30, 2026. Net product revenue reached $5... |
| 30 Jul 2026 |
8-K: Regulation FD Disclosure
CULVER CITY, Calif., July 29, 2026 — ImmunityBio, Inc. (NASDAQ: IBRX), a vertically integrated commercial-stage biotechnology company, today announced that the Emirates Drug Establishment (EDE) of the United Arab Emirates (UAE) has grant... |
| 06 Jul 2026 |
Form 4: Cohen Cheryl, Director
Received 55,979 shares by exercise or conversion ($167K) · Sold 131,210 shares ($1.25M) |
| 06 Jul 2026 |
Form 4: Selecky Christobel, Director
Received 159,478 shares by exercise or conversion ($476K) · Sold 159,478 shares ($1.44M) |
| 02 Jul 2026 | 144 |
| 01 Jul 2026 |
Form 4: Selecky Christobel, Director
Received 95,722 shares by exercise or conversion ($281K) · Sold 95,722 shares ($862K) · Received 1,000 shares by exercise or conversion ($2.98K) · 1 more |
| 01 Jul 2026 | 144 |
| 30 Jun 2026 | 144 |
| 29 Jun 2026 | 144 |
| 26 Jun 2026 |
Form 4: Simon Barry J., Director
Sold 25,000 shares ($197K) |
Loading...